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Abstract
Background: Dendritic cells (DCs) have the potential for cancer immunotherapy due to their ability to process and
present antigens to T-cells and also in stimulating immune responses. However, DC-based vaccines have only
exhibited minimal effectiveness against established tumours in mice and humans. The use of appropriate adjuvant
enhances the efficacy of DC based cancer vaccines in treating tumours.
Methods: In this study we have used tocotrienol-rich fraction (TRF), a non-toxic natural compound, as an adjuvant
to enhance the effectiveness of DC vaccines in treating mouse mammary cancers. In the mouse model, six-week-
old female BALB/c mice were injected subcutaneously with DC and supplemented with oral TRF daily (DC+TRF)
and DC pulsed with tumour lysate from 4T1 cells (DC+TL). Experimental mice were also injected with DC pulsed
with tumour lysate and supplemented daily with oral TRF (DC+TL+TRF) while two groups of animal which were
supplemented daily with carrier oil (control) and with TRF (TRF). After three times vaccination, mice were
inoculated with 4T1 cells in the mammary breast pad to induce tumour.
Results: Our study showed that TRF in combination with DC pulsed with tumour lysate (DC+TL+TRF) injected
subcutaneously significantly inhibited the growth of 4T1 mammary tumour cells as compared to control group.
Analysis of cytokines production from murine splenocytes showed significant increased productions of IFN-g and
IL-12 in experimental mice (DC+TL+TRF) compared to control, mice injected with DC without TRF, mice injected
with DC pulsed with tumour lysate and mice supplemented with TRF alone. Higher numbers of cytotoxic T cells
(CD8) and natural killer cells (NK) were observed in the peripheral blood of TRF adjuvanted DC pulsed tumour
lysate mice.
Conclusion: Our study show that TRF has the potential to be an adjuvant to augment DC based immunotherapy.
Background
There are several types of vaccines used for prevention
of infectious diseases, such as attenuated microorgan-
isms, recombinant proteins and DNA vaccines. Cur-
rently, studies are being carried out in developing
vaccines for tumours i.e. to activate the T-helper-1
(Th1) or cell-mediated arm of the immune system [1,2].
The cell-mediated arm of the immune system is crucial
in protecting the host against the onset, development
and spread of tumour. There are several ways to activate
the cell-mediated arm of the immune system such as
use of adjuvants, recombinant cytokines and nutritional
supplements.
Breast carcinoma is the most common cancer in
female and responsible for the largest numbers of can-
cer-related deaths in women. There are numerous stu-
dies looking at different approaches to inhibit or retard
the growth of breast cancer in animal models and clini-
cal trials [3-6]. One of these approaches involves the use
of dendritic cells (DC), which are well-known for their
potent ability as professional antigen-presenting cells
(APC). These cells possess unique properties that allow
these cells to elicit primary and boost secondary
immune responses as well as to regulate the type of T
cell- mediated immune response that is induced [7-9].
Several studies have demonstrated that tumour antigen-
pulsed DC cells are capable of inducing the generation
and proliferation of T-helper (Th) and cytotoxic T-lym-
phocytes (CTL) cells via by presenting tumour peptides
on their major histocompatibility complex (MHC) class I
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immunity [1,10,11].
Nutrition is an important aspect to maintain a healthy
and vigilant immune system. Hence, certain nutritional
products or supplement may provide a boost for host
immune system to fight tumour and this could improve
the outcome of treatment. We have previously shown
that vitamin E, namely the tocotrienol-rich fraction iso-
lated from palm oil is effective in inhibiting the growth
of human mammary cancer cell line in culture [5,12,13].
In this study, investigation on the effects of TRF supple-
mentation, a non-toxic natural compound from palm oil
to improve the efficacy of vaccines against breast cancer
in our BALB/C mouse model has been carried out.
Methods
Mice
Inbred female BALB/c mice (six to eight week-old) were
obtained from the Institute for Medical Research (IMR),
Kuala Lumpur and housed at the Animal Maintenance
Facility of the same institute. Animals were maintained
on commercially available pellet diet and water ad libi-
tum. The soda bedding was changed every three-to-four
days. All experiments with animals were performed in
accordance with the guidelines approved by the Ethics
Committee of the Institute for Medical Research (IMR),
Malaysia.
Cell line
Murine 4T1 cell line, a spontaneously metastatic tumour
cells derived from mammary gland tumour of BALB/c
mice was purchased from the American Type Culture
Collection (ATCC, Rockville USA). The 4T1 cells are
comparable to human stage IV breast cancer [14]. These
cells are poorly immunogenic and express surface MHC
class I but not MHC class II molecules. The tumour
cells were cultured in 25 ml cell culture flasks (Nunc,
Denmark) as recommended by the ATCC.
Medium and cytokines
Complete medium (CM) consisted of RPMI 1640 supple-
mented with 10% heat-inactivated foetal bovine serum,
1% Glutamine and 1% Penicillin/streptomycin. Recombi-
nant mouse cytokines were purchased from Chemicon
(USA) and used at the following concentrations: granulo-
cyte macrophage colony-stimulating factor (GM-CSF) 10
hg/ml; interleukin (IL)-4, 10 hg/ml; recombinant mouse
tumour necrosis factor (TNF)-a,2 0hg/ml.
Generation of bone marrow-derived DC
Murine bone marrow (BM) cells were harvested by
flushing the marrow cavities of femur and tibia bones of
six-to-eight week-old BALB/c mice with medium under
aseptic condition. Erythrocyte-depleted mouse bone
marrow cells were cultured in CM supplemented with
GM-CSF and IL-4 [6,15] in a humidified 5% CO2 incu-
bator (Heraeus, Germany). The medium was changed
every three to four days. On day six, TNF-a was added
to the DC cultures to induce maturation. The DC is
harvested between day seven to nine. Cell differentiation
was monitored by inverted microscopy. The expression
of FITC-CD11c (BD PharMingen, USA), FE-mouse
MHC class II and FITC-mouse CD86 (eBiosciences,
USA) were analysed after seven to nine days of culture
using a flow cytometer (FACS Callibur; BD Biosciences).
Cytotoxic assay
The 4T1 cells, BM-derived DC and mouse splenocytes
were plated at 1 × 10
5 cells/well in a microtitre plate and
i n c u b a t e da t3 7 ° Ci nah u m i d i f i e d5 %C O 2 incubator
(Heraeus, Germany) for 24 hours. The culture medium
was replaced with fresh culture medium containing dif-
ferent concentrations (2 to 30 μg/ml) of TRF in 0.1%
ethanol (final concentration v/v). Triplicate wells were
used for each treatment. Control cells were incubated in
complete RPMI 1640 medium containing just 0.1% etha-
nol (v/v). The cells were incubated at 37°C, 5% CO2 incu-
bator (Heraeus, Germany) for 72 hours. After 72 hours,
cell proliferation was determined using MTT cell prolif-
eration assay according to the manufacturer’s recommen-
dations (Chemicon, USA). Percentage cell viability at
different concentrations of TRF treatment was calculated
based on the proliferation of the untreated control cells.
Preparation of tumour cell lysate and antigen
pulsing of DC
The 4T1 cells were cultured in the presence or absence on
8 μg/ml of TRF in T25 culture flasks overnight. The TRF-
treated confluent 4T1 cells were harvested in a 15 ml tube
(Falcon, USA). The cells were then resuspended in 1 ml
complete medium. Tumour lysate (TL) was prepared by
subjecting these cells three-to-five cycles of freezing in
liquid nitrogen and thawing at 65°C. The cell lysates were
spun at 2000 rpm for 5 min to remove particulate cellular
debris. Untreated 4T1 cells were used as control.
Inductions of IFN-g and IL-12 released in
DC culture in vitro
Freshly generated DC were plated at 1 × 10
6 cells/well
in a 24-well plate overnight to allow the DC to adhere
to the culture well. The medium was changed on the
following day and 1 ml of tumour lysate preparation
from TRF treated or untreated 4T1 cells were added to
each well. After 72 h, the culture supernatants were col-
lected. The amounts of IFN-g and IL-12 in the culture
supernatants were determined by a commercial ELISA
according to manufacturer’s recommendations (BD
Biosciences, USA).
Preparation of tumour lysate-pulsed DC for
injection into mice
The freshly generated DC were incubated for 18 hours
with tumour lysate from 4T1 cells and cultured in the pre-
sence or absence of TRF at a 1:1 ratio (DC:4T1). Following
this, the TL-pulsed DCs were collected, washed three
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Cell count was adjusted to 10 × 10
6 cells/ml in medium
and this preparation was used for injection into mice.
Ability of DC vaccinations and TRF supplementation to
inhibit tumour growth in BALB/c mice
Five groups of five mice each were used for this study.
T h em i c ei nD C + T Lg r o u pw e r ei n j e c t e ds u b - c u t a -
neously (s.c) in the left flank with 0.1 ml of 1 × 10
6 DC
pulsed tumour lysate from 4T1 cells. The mice in
DC+TRF group were injected sub-cutaneously (s.c.) in
t h el e f tf l a n kw i t h0 . 1m lo f1×1 0
6 fresh DC. These
mice were supplemented daily with oral TRF oil. The
mice in DC+TL+TRF group were injected sub-cuta-
neously (s.c.) in the left flank with 0.1 ml of 1 × 10
6 DC
pulsed tumour lysate and supplemented daily with TRF
oil. The mice in TRF and control groups have not been
treated with any DC injection but were supplemented
with TRF and carrier oil daily. These injections were
r e p e a t e do nd a y7a n d1 4 .O nd a y2 8 ,t h em i c ei na l l
five groups were injected with a single s.c. containing
1×1 0
3 (0.05 ml) 4T1 cells in the right flank of their
mammary breast pad. The mice were monitored daily
for tumour growth and their body weight was recorded
every week. Once tumour was palpable, the diameter of
the tumour was measured using a calliper (Mitutoyo,
Japan) as described previously [16]. After the mice were
sacrificed, blood and spleen samples were collected for
various analyses. The experiment was repeated twice.
Analysis of whole blood by flow-cytometry
When the mice were sacrificed, blood was collected by
heart puncture into heparinised tubes. The blood was
stained with a number of monoclonal antibodies, includ-
ing FITC-anti-mouse CD8a (BD PharMingen, USA) and
FITC- Pan-NK cells-DX5 (BD PharMingen, USA) for
flow-cytometry (FACSCallibur, Becton Dickinson, USA)
analysis.
IFN-g and IL-12 secretion assay in splenocytes culture of
experimental mice
For measurement of T-cell proliferation, the spleen was
removed aseptically when the mice were sacrificed. The
splenocytes (1 × 10
5 cells/well) were cultured for 72 h
in culture medium supplemented with 10 μg/ml Conca-
navalin A (Con A) in a humidified CO2 incubator (Her-
aeus, Germany) at 37°C. After 72 h, the splenocyte
culture was transferred into a sterile 1.5 ml tube and
centrifuged (200 g × 5 min) to recover the culture
supernatant. The amounts of IFN-g and IL-12 in the
culture supernatants were determined using a commer-
cial ELISA kit (BD Biosciences, USA).
Statistical analysis
The statistical significance of differential findings
between experimental groups and control were deter-
mined using Student’s t test. Significant values were
indicated when two-tailed P values < 0.05.
Results
Characterisation of DC by using CD11c
The DC population was characterised using FITC-conju-
gated CD11c monoclonal antibody (BD PharMingen,
USA). The results showed that more than 90% of DCs
expressed CD11c in both TRF-treated and untreated DC
after compared with unstained DC (see Fig. 1a (i) &1a
(ii)). In Fig. 1b and 1c, the results showed that CD86 and
MHC class II molecules also expressed more than 90% of
DCs in both treated and untreated DC, but slightly
higher in treated DC compared to untreated DC. The
pictures of DC were taken by microscopy (Carl Zeiss,
Germany) on day 0, 5, 7 and 9 are shown in Fig. 2. The
dendrites were visible by day 5 and had multiplied by day
7 and 9. A similar growth pattern was observed for the
size of the cells.
TRF induces cell death in 4T1 tumour cells
The effect of TRF treatment on the viability of 4T1 cells,
murine lymphocytes, and dendritic cells in-vitro after 72
h exposure to different concentrations of TRF was eval-
uated. The results show that TRF treatment inhibited
the growth of 4T1 cells in a dose dependent manner
(Fig. 3a). The inhibitory concentration, IC50 value of
TRF for 4T1 cells was found to be 8 μg/ml. The viability
of DC and splenocytes treated with TRF increased up to
25 μg/ml and (Fig. 3b) and 20 μg/ml (Fig. 3c) of TRF,
respectively. Based on these findings, the concentration
of TRF used in the preparation of tumour lysate from
4T1 cells for further studies was 8 μg/ml TRF as at this
concentration it caused death in 50% of 4T1 cells but
had no detrimental effect on the DC or splenocytes.
IFN-g an IL-12 released by DC after incubated with
tumour lysate from 4T1
Co-culturing of the DC with increasing concentrations
o fT R F( 2t o1 5μg/ml) resulted in a dose-dependent
increase in the production of IFN-g by the DC (see
Fig. 4a). Similar pattern for IFN-g production was identi-
fied in splenocytes culture (see Fig. 4b). An increase in
the production of IFN-g was also observed with DC co-
cultured with tumour lysate from 4T1 cells (see Fig. 4c).
However, the production of IFN-g was significantly (p <
0.05) augmented when 8 μg/ml TRF was added to this
culture (see Fig. 4c). In Fig. 4d and 4e, the productions
of IL-12 also increased with higher concentrations of
TRF in DC and splenocytes cultures. Significant increase
of IL-12 production was also detected in DC +TL+TRF
treatment (see Fig. 4f).
Pre-treatment with tumour lysate pulsed DC and TRF
supplementation can inhibit tumour growth in BALB/c
mice and enhance production of IFN-g splenic leucocytes
The effect of pre-treatment of mice with DC+TL+TRF
to inhibit induction and growth of tumour was assessed
using a mouse model of breast cancer. All the mice in
the untreated control group rapidly developed tumour
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Figure 1 (a) DCs stained with CD11c monoclonal antibody, i) untreated DC was stained with CD11c compared with unstained DC.
ii) Stained DC treated with 8 μg/ml of TRF compared with unstained DC. (b) DCs stained with CD86, i) untreated DC. ii) DC treated with 8 μg/
ml of TRF. (c) DCs stained with MHC class II, (i) untreated DC. ii) DC treated with 8 μg/ml of TRF.
Abdul Hafid et al. BMC Cancer 2010, 10:5
http://www.biomedcentral.com/1471-2407/10/5
Page 4 of 10Figure 2 Pictures of DC taken by microscopy with 100× magnification at day 0, 5, 7 and 9.
Figure 3 Viability of (a) 4T1 cells decreased after treated with different concentrations of TRF. IC50 recorded at 8 μg/ml of TRF treatment.
b) Viability of DC increased in higher concentration of TRF up to 25 μg/ml. c) Splenocytes culture treated with different concentrations of TRF
showed increased cell viability until 20 μg/ml of treatment.
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pulsed DC (DC+TL) prior to the inoculation of 4T1
cells, significantly (p < 0.05) delayed tumour growth and
size as compared to mice in the untreated control group
(see Fig 5, Table 1). However, all the mice in the
DC+TL group progressively developed tumours, albeit to
a lesser size. In group supplemented with TRF alone
(TRF group), the development of tumour was detected at
week 3 and by week 6, the number of mice with tumour
increase where three out of five mice (3/5) had tumour.
At the end of the experiment, four mice in TRF group
developed tumour but the size of the tumours was smal-
ler compared to tumours developed by the mice in the
DC+TL group. In the DC+TRF group, three out of five
mice (3/5) developed tumour in the final week and the
tumour growth remained static. In contrast, all the mice
(5/5) treated with the combination of tumour lysate-
pulsed DC pre-treatment and TRF supplementation
(DC+TL+TRF) were protected against tumour growth up
to week five (see Fig. 5, Table 1). However, two (2/5) of
the mice in this group developed palpable tumours that
remained static for several weeks. The remaining three
(3/5) mice in this group remained tumour-free.
We also measured the amounts of IFN-g and IL-12
produced by Con A-stimulated splenocytes from the
c o n t r o la n dt r e a t e dm i c e( s e eF i g .6 a& 6 b ) .T h es p l e n o -
cytes from mice that were treated with tumour lysate
pulsed DC and daily supplementation of TRF (DC+TL
+TRF) produced high amounts of IFN-g (1346 pg/ml).
The amount of IFN-g produced by splenocytes cultured
from the mice that only received tumour lysate pulsed
DC (DC+TL) treatment and control were 700 pg/ml
and 520 pg/ml, respectively. The splenocytes from the
Figure 4 The amount of IFN-g produced by (a) DCs treated with different concentrations of TRF (2 to 15 μg/ml) and (b) splenocytes
treated with different concentrations of TRF (2 to 15 μg/ml) (c) DCs co-cultured with tumour lysate from 4T1 cells in the presence of
8 μg/ml TRF for 72 h. Following 72 hours of culture, the supernatants of control, TRF alone, DC with tumour lysate from 4T1 cells (DC+TL), DC
with 8 ug/ml of TRF (DC+TRF), DC with tumour lysate from 4T1 cells and 8 μg/ml TRF (DC+TL+TRF) were harvested. The amount of IFN-g in the
supernatant was determined using ELISA. The amount of IL-12 produced by (d) DCs treated with different concentrations of TRF (2 to 15 μg/ml)
and (e) splenocytes treated with different concentrations of TRF (2 to 15 μg/ml) (f) DCs co-culture with tumour lysate (DC+TL), in the presence
of 8 ug/ml TRF (DC+TL+TRF), DC alone in the presence of ug/ml TRF (DC+TRF), TRF alone and control for 72 h.
Table 1 The number of BALB/c mice developed tumour in
each group.
Week after
inoculation
Number developed tumour
Control
(n = 5)
TRF
(n = 5)
DC + TL
(n = 5)
DC + TRF
(n = 5)
DC + TL +TRF
(n = 5)
10 0 0 0 0
23 0 0 0 0
35 1 1 0 0
45 2 2 2 0
55 3 3 3 0
65 3 5 3 2 *
7** 5 4 5 3* 2*
* palpable and static
** end of experiment
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Page 6 of 10Figure 5 Tumour size of the tumours induced in the control, TRF alone, DC+TL, DC+TRF and DC+TL+TRF groups were measured.
The DC+TL group were injected with DC that has been primed with tumour lysate from 4T1 cells and received daily oral supplementation of
carrier oil while the DC+TL+TRF group were injected with DC primed with tumour lysate from 4T1 cells and supplemented daily with 1 mg/ml
TRF orally. For the TRF alone, mice were only supplemented with TRF oil daily and for DC+TRF, DC fresh without tumour lysate and
supplemented with TRF oil daily.
Figure 6 Splenocytes (1 × 10
5 in each well) harvested from each group were cultured in the presence of 1 μg/ml Con A for 72 hours
in 96 well plate. The culture supernatant was collected and (a) IFN-g produced was measured by using an ELISA kit. (b) IL-12 produced was
measured by using an ELISA kit.
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760 pg/ml and 900 pg/ml. In general, IFN-g produced
by splenocytes from TRF supplemented mice was higher
compared to non-TRF groups. For IL-12 productions,
combination of tumour lysate pulsed DC with oral sup-
plementation of TRF i.e. the (DC+TL+TRF) group pro-
duced higher amounts of IL-12 (152 pg/ml) compared
to others (control = 51 pg/ml, TRF = 112 pg/ml, DC
+TL = 103 pg/and DC+TRF = 123 pg/ml). These find-
ings demonstrated that systemic administration of TRF
could enhance the efficacy of tumour lysate pulsed DC
immunisation in vivo and protective immunity to lethal
tumour challenge.
Immune regulation detected in the peripheral blood of
treated mice groups
The percentages of natural killer (NK) cells and CD8
+ T-
cells as assessed by flow cytometry are shown in Fig. 7.
There was an apparent increased in the percentages of
NK and CD8
+ T-cell in the DC+TL+TRF group. The
date shows that immunisation of BALB/c mice with
tumour lysate pulsed DC together with oral gavage of
1 mg TRF (DC+TL+TRF group) daily can increase the
numbers of NK cells and CD8
+ T-cells, which could in
turn lead to enhancement of the cell-mediated arm of the
immune system that is crucial to fight tumours.
Discussion
We have used a murine model of breast cancer where
t u m o u rg r o w t hi ns y n g e n e i cf e m a l eB A L B / cm i c ei s
induced by a single s.c. injection of 1 × 10
3 4T1 cells in
the right flank of the mice. The 4T1 tumour model clo-
sely resembles human breast cancer because its poor
immunogenicity and ability to spontaneously metastasise
to lungs, liver, bone marrow and brain [16,17]. This
model was used to evaluate the efficacy of oral supple-
mentation of TRF to enhance the therapeutic benefits of
DC immunotherapy in treating breast cancer in a
mouse model.
Our results showed that TRF on its own, in both the
in-vitro or in-vivo m e t h o d su s e di nt h i ss t u d yc a n
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Figure 7 The percentage of a) NK cells and b) CD8
+ T-lymphocytes in the control and experimental groups were determined by flow
cytometric analyses.
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induced by these cells. This study corroborates with pre-
vious reports of other tumour models [12,18,19]. In this
study, we show for the first time, that the combination
of using two therapeutic approaches i.e. three injections
of tumour-lysate pulsed DC prior to inoculation of
tumour cells and daily TRF supplementation can signifi-
cantly inhibit the growth of tumour as well as improve
the overall survival of mice induced with tumour.
The MTT assay showed that 2 μg/ml TRF could inhi-
bit the proliferation of 4T1 tumour cells in vitro.H o w -
ever, TRF at this concentration did not exhibit any anti-
proliferative effect of DC or murine splenocytes (Fig. 3b
&3c). The IC50 value of TRF for 4T1 cells was deter-
mined to be 8 μg/ml. Although there was a slight
increase in the CD11c expression by TRF-treated DCs
compared to control, this increase was not statistically
significant. The DC+TL+TRF treatment yielded signifi-
cantly higher production of IFN-g by the DC. In addi-
tion, the DC pulsed with tumour lysate from 4T1 cells
could enhance the productions of IFN-g and IL-12 by
T-helper-1 cells when these cells were cultured in the
presence of 8 μg/ml TRF. These findings show that TRF
is a potent compound that can induce the immune sys-
tem to release cytokines that promote cell mediated
immune response.
In the animal model, mice that were injected with DC
pulsed with tumour lysate from 4T1 cells and supple-
mented daily with oral TRF showed marked reduction
in tumour onset and growth. Previous reports by Nesar-
etnam and co-workers [12,13,19-21] have shown that
tocotrienol on its own can inhibit growth of human
breast cancer cells in vitro [12,19] as well as in athymic
nude mice [21]. The combination of tumour lysate
pulsed-DC and TRF supplementation observed in this
study could inhibit the growth of breast tumour in the
mouse model. As shown in Fig. 5 and Table 1, the inci-
dence of tumour in the DC+TL+TRF group showed
smaller tumour burden compared to control group and
DC+TL group, TRF group and DC+TRF group. The
splenocytes from the DC+TL+TRF group produced the
highest amount of IFN-g (1346 pg/ml) compared to the
DC+TL group (700 pg/ml), control untreated group
(520 pg/ml), TRF group (760 pg/ml) or DC+TRF group
(900 pg/ml). The IL-12 amount produced in splenocytes
culture from experimental mice showed similar pattern
as IFN-g. There was a significant higher production of
IFN-g and IL-12, which are the two signature cytokines
for Th1 response, by splenocytes from the DC+TL+TRF
group which also suggest that the combination therapy
has been effective in enhancing a cell-mediated immune
response in these mice. Interferon-g also promotes
class-switching to IgG isotype, which is a key compo-
nent of cell mediated immunity [22]. This cytokine also
upregulates the expression of class II MHC molecules
and B7 co-stimulatory molecules on antigen presenting
cells. For IL-12, it is expressed specifically in macro-
phages and dendritic cells [17,23] and plays a central
role in mediating cell mediated immunity, promoting
differentiation of CD4+ T cells to the Th1 subset and
of CD8
+ T cells into mature cytotoxic T lymphocytes
(CTLs) [24]. IL-12 is also a potent stimulator of NK
cells as well as enhancing cytocidal anti tumour
immune responses [25,26]. All these actions could serve
to amplify T-cell responses [22]. Our findings are in
agreement with that reported by Ramanathapuram and
co-workers [2], who showed that combination therapy
using alpha-tocopheryl succinate (a-TOS) and DCs (a-
TOS+DC) increased IFN-g production by CD4
+ and
CD8
+ T lymphocytes. The a-TOS is an esterified analo-
gue of vitamin E used as an adjuvant to demonstrate
the inhibitions of 3LL tumours in vitro and in C57BL/6
mice model. In our study, we used tocotrienol-rich frac-
tion (TRF), which contains the natural isomers of vita-
m i nE .T h eT R Fc a nb ef o u n da b u n d a n t l yi np a l mo i l
was used as an adjuvant to develop cancer vaccine in
this study because TRF could inhibit the growth of
murine mammary cancer (4T1) and human breast can-
cer (MCF-7 & MDA) cells. In addition, when the DC
were co-cultured with TRF, there was a significant
increase in the production of IFN-g by the DC. These
are important properties for an adjuvant to be used in a
tumour model to have as it could promote Th1
immune responses.
Both NK cells and CD8
+ T-cells have a crucial role in
the recognition and removal of tumour cells [27-29].
The NK cell activation induced by tumour cells can
directly promote anti-tumour responses. Although acti-
vation of CD8
+ T-cells is more complex, it is important
for the development of tumour-specific memory T-cells,
which is responsible for long-term protection against
the same tumour [28]. The percentages of NK cells and
CD8
+ T-cells increased in the TRF supplemented group
compared to the control and DC+TL only group. Thus,
the combine therapy of using DC+TL and daily oral
TRF supplementation can promote tumour-specific
immune responses in this mouse model of breast
cancer.
Conclusion
In conclusion, this study reports on the ability of TRF to
a c ta sa na d j u v a n tt h a tp r o m o t e st u m o u r - s p e c i f i cc e l l -
mediated immune response in mice. The daily TRF sup-
plementation augments the protective effect provided by
three vaccinations of DC pulsed with tumour lysate
from 4T1 cells in this mouse model. Further studies are
needed to investigate in detail the effectiveness of TRF
adjuvanted DC immunotherapy.
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4T1 cell: Mouse mammary cancer cell; APC: antigen-presenting cells; ATCC:
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medium; CO2: carbon dioxide; Con A: concanavalin A; CTL: cytotoxic
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colony-stimulating factor; IFN-g: Iinterferon-gamma; IL-4: interleukin 4; IL-12:
interleukin 12; MHC: major histocompatibility complex; NK cell: natural killer
cell; s.c: sub-cutaneously; Th-1: T-helper-1; TL: Tumour lysate; TNF: tumour
necrosis factor; TRF: tocotrienol-rich fraction.
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